A1BG and neoplasm: Despite the fact that our data imply that dimers are the preferred choice for further exploration to improve the potency of GABs, a potential downside of the introduction of additional multimerization domains in the GAB is that these larger multimers might substantially increase the space between the tumor- and CD3-binding domains, which could lead to a decreased activation efficacy, due to suboptimal immune synapse distances.